Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0001140361-25-004495
Filing Date
2025-02-14
Accepted
2025-02-14 07:00:08
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 6414
  Complete submission text file 0001140361-25-004495.txt   7876
Mailing Address 55 FLEMINGTON ROAD NORTH MELBOURNE C3 3051
Business Address 55 FLEMINGTON ROAD NORTH MELBOURNE C3 3051 61 3 9093 3855
Telix Pharmaceuticals Ltd (Subject) CIK: 0002007191 (see all company filings)

EIN.: 000000000 | State of Incorp.: C3 | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-94874 | Film No.: 25623138
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address C/O TELIX PHARMACEUTICALS LTD 55 FLEMINGTON ROAD NORTH MELBOURNE C3 3051
Business Address
Kluge Andreas (Filed by) CIK: 0002037921 (see all company filings)

Type: SCHEDULE 13G